TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03335956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 120mg
Description: CORT125281 is supplied as capsules for oral dosing once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 180mg
Description: CORT125281 is supplied as capsules for oral dosing twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 240mg
Description: CORT125281 is supplied as capsules for oral dosing twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg
Description: CORT125281 is supplied as capsules for oral dosing once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily
Study: NCT00847938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: 0.04 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: 0.02 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: 0.01 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
Study: NCT04678011

Intervention type: PROCEDURE
Intervention: Personalized surveillance and intervention protocol
Description: This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
Study: NCT03424889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Description: Nasal administration of Xylometazoline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nasal administration of 0.9% Saline
Study: NCT01827930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate 600 MG Oral Tablet
Description: Imatinib Mesylate for CP CML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate 400 MG Oral Tablet
Description: Imatinib Mesylate for CP CML

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib Mesylate
Description: Imatinib Mesylate for CP CML
Study: NCT00413335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: 2mg to begin then 4mg, twice daily for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject receives placebo.
Study: NCT00253318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40 mg/m\^2 IV over 1 hour on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 30 mg orally on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
Study: NCT00545987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid™ Delivery System
Description: Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional intramuscular injection
Description: administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
Study: NCT03434704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning treatment Thiotepa-Treosulfan-Fludarabine
Description: Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age \> 65 years.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC graft
Description: (target 4-8 × 106 CD34+ cells/kg patient body weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GvHD prophylaxis
Description: Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: \>80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primary antifungal prophylaxis
Description: Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
Study: NCT01911013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior cervical discectomy and fusion
Description: anterior cervical discectomy and fusion with anterior plating or not

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cervical discectomy and fusion
Description: anterior cervical discectomy and fusion with anterior plating or not

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cage and Plate
Description: anterior cervical discectomy and fusion is performed using cervical cage and plate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cage alone
Description: anterior cervical discectomy and fusion is performed using cage alone with plate.
Study: NCT01889628

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liquid-based Nutritional Formulae and liquid glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liquid-based Nutritional Formulae and liquid glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liquid-based Nutritional Formulae and liquid glucose
Study: NCT02905942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
Study: NCT00921882

Intervention type: PROCEDURE
Intervention: Oral glucose tolerance test
Description: Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
Study: NCT01427283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone controlled-release
Description: Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl controlled-release
Description: Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Study: NCT02483104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
Study: NCT00226018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Adapter (Organon, Oss, the Netherlands)
Description: Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00652028

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine, midazolam; fentanyl
Description: Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine, midazolam; fentanyl
Description: Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
Study: NCT02483104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered on Day 1 of each cycle, intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
Study: NCT01974986

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water with flavoring and non-nutritive sweetener.
Description: A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Na low-CHO beverage
Description: A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Na high-CHO beverage
Description: A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
Study: NCT01221688

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillar Sentinel lymph node biopsy
Description: Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNB and complete level I-II axillary lymphadenectomy
Description: group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
Study: NCT02451436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Media Use Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study Skills Control Group
Study: NCT02491502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: HIFU Under ultrasound guidance
Study: NCT04905875

Intervention type: PROCEDURE
Intervention: Prone Position
Description: Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
Study: NCT01264159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung impedence-guided therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual treatment of patients with developing acute heart failure
Study: NCT04455178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide
Description: indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
Study: NCT00812422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: one dose of Dexibuprofen 2.5 or 5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: one dose of Dexibuprofen 3.5 or 7 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: one dose of Ibuprofen 5 or 10 mg/kg
Study: NCT00869986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dirucotide
Description: 500mg, intravenous, every 6 months for 15 months
Study: NCT00226018

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04386356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope
Description: Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
Study: NCT02411526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX003 (Risperidone-SABER®)
Description: ZX003 administered as a SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX003 (Risperidone-SABER®)
Description: ZX003 administered as a SC injection
Study: NCT00869986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous, once every six months for 15 months
Study: NCT02978924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tsDCS
Description: 20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tsDCS
Description: 20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
Study: NCT01576094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
Study: NCT01435226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD
Study: NCT00724932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
Study: NCT00332917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12-42 mg
Study: NCT01499199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg Once Daily
Study: NCT02662894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg + Rosuvastatin 20mg
Description: 1 tablet, oral, a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 320mg + Rosuvastatin 20mg
Description: 1 tablet, oral, a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan® 160mg + Crestor® 20mg
Description: Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan® 320mg + Crestor® 20mg
Description: Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Study: NCT05631210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Privacy agreements with pictograms
Description: The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
Study: NCT04065113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)
Description: Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)
Description: Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage of Subdural Hematoma
Description: Drainage of subdural hematoma via burrhole or craniotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage of Subdural Hematoma
Description: Drainage of subdural hematoma via burrhole or craniotomy
Study: NCT00573482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDE
Description: The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
Study: NCT02317965

Intervention type: OTHER
Intervention: Maternal Blood Draw
Description: Maternal Blood Draw
Study: NCT03069313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
Study: NCT04152694

Intervention type: OTHER
Group type: OTHER
Intervention: Ceftaroline levels in CRRT
Description: Levels of ceftaroline measured in patients receiving CRRT
Study: NCT01435226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegobuvir
Description: tegobuvir 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegobuvir
Description: tegobuvir 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match tegobuvir
Description: tegobuvir placebo BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match RBV
Description: Ribovirin placebo BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
Study: NCT04320979

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: internal mammary nodal irradiation
Description: chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
Study: NCT02411526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX003 (Risperidone-SABER®)
Description: ZX003 administered as a SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal Consta
Description: Risperdal Consta administered as a IM injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
Study: NCT00208494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Replacement
Description: Total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement
Description: Total hip replacement